Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial.
Saved in:
| Title: | Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial. |
|---|---|
| Authors: | Raket LL; Eli Lilly and Company, Indianapolis, Indiana, USA., Lu M; Eli Lilly and Company, Indianapolis, Indiana, USA., Evans CD; Eli Lilly and Company, Indianapolis, Indiana, USA., Zimmer JA; Eli Lilly and Company, Indianapolis, Indiana, USA., Sparks J; Eli Lilly and Company, Indianapolis, Indiana, USA., Collins EC; Eli Lilly and Company, Indianapolis, Indiana, USA., Shcherbinin S; Eli Lilly and Company, Indianapolis, Indiana, USA., Wang H; Eli Lilly and Company, Indianapolis, Indiana, USA., Nery ESM; Eli Lilly and Company, Indianapolis, Indiana, USA., Epelbaum S; Eli Lilly and Company, Indianapolis, Indiana, USA., Dell'Agnello G; Eli Lilly and Company, Indianapolis, Indiana, USA., Brooks DA; Eli Lilly and Company, Indianapolis, Indiana, USA., Sims JR; Eli Lilly and Company, Indianapolis, Indiana, USA., Mintun MA; Eli Lilly and Company, Indianapolis, Indiana, USA. |
| Source: | Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2026 Jun; Vol. 22 (6), pp. e71577. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: John Wiley & Sons, Ltd Country of Publication: United States NLM ID: 101231978 Publication Model: Print Cited Medium: Internet ISSN: 1552-5279 (Electronic) Linking ISSN: 15525260 NLM ISO Abbreviation: Alzheimers Dement Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1552-5279 |
|---|---|
| DOI: | 10.1002/alz.71577 |
